Yumanity Therapeutics (Yumanity Therapeutics) Days Sales Outstanding : 0.00 (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Days Sales Outstanding?

Yumanity Therapeutics's average Accounts Receivable for the three months ended in Sep. 2022 was $0.00 Mil. Yumanity Therapeutics's Revenue for the three months ended in Sep. 2022 was $1.40 Mil. Hence, Yumanity Therapeutics's Days Sales Outstanding for the three months ended in Sep. 2022 was 0.00.

The historical rank and industry rank for Yumanity Therapeutics's Days Sales Outstanding or its related term are showing as below:

YMTX's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.38
* Ranked among companies with meaningful Days Sales Outstanding only.

Yumanity Therapeutics's Days Sales Outstanding stayed the same from Sep. 2021 (0.00) to Sep. 2022 (0.00).

Yumanity Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Yumanity Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Days Sales Outstanding Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Days Sales Outstanding

226.88

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Days Sales Outstanding	Get a 7-Day Free Trial							-	598.75	445.99	-	-

Competitive Comparison of Yumanity Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Yumanity Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yumanity Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Yumanity Therapeutics's Days Sales Outstanding falls into.

Yumanity Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Yumanity Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as

	Days Sales Outstanding (A: Dec. 2021 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2020 )	+	Accounts Receivable (A: Dec. 2021 ))	/	count )	/	Revenue (A: Dec. 2021 )	*	Days in Period
=	( (0	+	5)	/	1 )	/	8.044	*	365
=	5					/	8.044	*	365
=	226.88

Yumanity Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2022 is calculated as:

	Days Sales Outstanding (Q: Sep. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Sep. 2022 ))	/	count )	/	Revenue (A: Sep. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	1.402	*	365 / 4
=	0					/	1.402	*	365 / 4
=	0.00

Yumanity Therapeutics (NAS:YMTX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Yumanity Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Yumanity Therapeutics (Yumanity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (NAS:YMTX) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Executives

Shawn Iadonato	director, officer: Chief Executive Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips	officer: President	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Raymond J. Bartoszek	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker	officer: Chief Financial Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny	officer: General Counsel	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux	officer: Chief Scientific Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Richard Peters	director, officer: President & CEO	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Devin Whittemore Smith	officer: SVP and General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Marie Epstein	officer: Principal Accounting Officer	C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Michael D Wyzga	officer: See Remarks	C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Paulash Mohsen	officer: Chief Business Officer	C/O YUMANITY THERAPEUTICS, INC., 40 GUESS STREET SUITE 4410, BOSTON MA 02135
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma	officer: EVP, Head of R&D	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
N Anthony Coles	director, officer: Executive Chair	MORRIS CORP. CENTER I; BLDG. B; 4TH FLR., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054